Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000543559 | SCV000637007 | uncertain significance | Brugada syndrome | 2024-11-10 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 822 of the SCN10A protein (p.Ala822Val). This variant is present in population databases (rs747839312, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with SCN10A-related conditions. ClinVar contains an entry for this variant (Variation ID: 463240). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SCN10A protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV002274062 | SCV002559577 | uncertain significance | not provided | 2022-07-14 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002431588 | SCV002731666 | uncertain significance | Cardiovascular phenotype | 2024-05-17 | criteria provided, single submitter | clinical testing | The p.A822V variant (also known as c.2465C>T), located in coding exon 15 of the SCN10A gene, results from a C to T substitution at nucleotide position 2465. The alanine at codon 822 is replaced by valine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002497115 | SCV002816806 | uncertain significance | Episodic pain syndrome, familial, 2 | 2021-10-12 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV002274062 | SCV005189671 | uncertain significance | not provided | criteria provided, single submitter | not provided |